LOGIN  |  REGISTER
Chimerix
Terns Pharmaceuticals

Elevance Health Releases Impact Report

July 08, 2024 | Last Trade: US$401.36 10.63 2.72

INDIANAPOLIS / Jul 08, 2024 / Business Wire / Elevance Health released its annual Impact Report, highlighting its continued evolution from a traditional health insurance benefits company to a diversified healthcare services organization.

The report details significant achievements including the industry-leading Health Equity Accreditation Plus from the National Committee for Quality Assurance, support for Medicaid eligibility renewals, and growth of Carelon.

In Elevance Health’s ongoing efforts to make a meaningful and healthy impact on communities, its workforce, and the environment, the organization was again included in America’s top 50 most community-minded companies and JUST Capital’s JUST 100. Elevance Health is especially proud of its associates and their enthusiastic participation in connecting with members who are socially isolated or living with serious or terminal illness.

Emphasized throughout the Impact Report is Elevance Health’s progress on serving the unique needs of each health plan member, building capabilities to assess and address the key drivers of health, creating partnerships in communities to implement solutions to healthcare challenges, and using data-driven insights to simplify, connect and personalize healthcare.

Explore the full report

Stock Quote

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

Featured Stock

Amneal Pharmaceuticals

Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page